Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: A prospective observational study

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 10, 2014, Pages 2841-2847

  Prahl, Julie B ^a   Johansen, Isik S ^b,d   Cohen, Arieh S ^a   Frimodt Møller, Niels ^b   Andersen, Åse B ^c,d  

^a STATENS SERUM INSTITUT   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anti tuberculosis drugs; Therapeutic drug monitoring; Tuberculosis

Indexed keywords

C REACTIVE PROTEIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DENMARK; DRUG BLOOD LEVEL; DRUG MONITORING; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LUNG TUBERCULOSIS; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RELAPSE; RISK FACTOR; TANDEM MASS SPECTROMETRY; TREATMENT FAILURE; TIME; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; DRUG MONITORING; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 84928340190     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku210     Document Type: Article

References (28)

1. Lillebaek T, Poulsen S, Kok-Jensen A. Tuberculosis treatment in Denmark: treatment outcome for all Danish patients in 1992. Int J Tuberc Lung Dis 1999; 3: 603-12.
2. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-83.
3. Heysell SK, Moore JL, Keller SJ et al. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010; 16: 1546-53.
4. McIlleron H, Wash P, Burger A et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50: 1170-7.
5. Tappero JW, Bradford WZ, Agerton TB et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005; 41: 461-9.
6. Babalik A, Babalik A, Mannix S et al. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J 2011; 18: 225-9.
7. Um SW, Lee SW, Kwon SY et al. Low serum concentrations of antituberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis 2007; 11: 972-8.
8. Kimerling ME, Phillips P, Patterson P et al. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998; 113: 1178-83.
9. Mehta JB, Shantaveerapa H, Byrd RP Jr. et al. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001; 120: 1520-4.
10. Chideya S, Winston CA, Peloquin CA et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48: 1685-94.
11. Van Tongeren L, Nolan S, Cook VJ et al. Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis 2013; 17: 221-4.
12. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55: 169-77.
13. Pasipanodya JG, McIlleron H, Burger A et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208: 1464-73.
14. Srivastava S, Pasipanodya JG, Meek C et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951-9.
15. Narita M, Hisada M, Thimmappa B et al. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin Infect Dis 2001; 32: 515-7.
16. Chang KC, Leung CC, Yew WW et al. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur J Clin Microbiol Infect Dis 2008; 27: 467-72.
17. Burhan E, Ruesen C, Ruslami R et al. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother 2013; 57: 3614-9.
18. van Crevel R, Alisjahbana B, de Lange WCet al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis 2002; 6: 497-502.
19. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?. Antimicrob Agents Chemother 2005; 49: 1733-8.
20. Donald PR, Parkin DP, Seifart HI et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 2007; 63: 633-9.
21. Smythe W, Khandelwal A, Merle C et al. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob Agents Chemother 2012; 56: 2091-8.
22. Loos U, Musch E, Jensen JC et al. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 1985; 63: 1205-11.
23. Peloquin CA, Namdar R, Dodge AA et al. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999; 3: 703-10.
24. Peloquin CA, Namdar R, Singleton MD et al. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999; 115: 12-8.
25. Peloquin CA, Bulpitt AE, Jaresko GS et al. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy 1998; 18: 1205-11.
26. Peloquin CA, Bulpitt AE, Jaresko GS et al. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999; 43: 568-72.
27. Jayaram R, Shandil RK, Gaonkar S et al. Isoniazid pharmacokineticspharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48: 2951-7.
28. Jayaram R, Gaonkar S, Kaur P et al. Pharmacokineticspharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2118-24.